Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Updates (for clubhouse)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1168)
•••
Comment by Pandoraon Feb 26, 2021 11:24pm
190 Views
Post# 32677871

RE:RE:RE:RE:RE:Updates (for clubhouse)

RE:RE:RE:RE:RE:Updates (for clubhouse)
Pragmatist wrote:
Pandora wrote:
Pragmatist wrote: Many thanks for taking the time to post that, Pandora.  It hasnt happened to me often, but I notice others have experienced the same issue. It has since been working fine for me.

I have saved your post for future reference.

 


Did you try it out? Did it work alright?


The ads did not disapperar.  But I will try it again if I have the same issue of the ads overlaying the post section.  Thanx again

I can't take credit for it - I'm not that sharp - I got it from a guy on another board and it stuck with me.




As soon as you click on the check mark in the box beside "width" both the check mark and the ads should disappear. Then click on "x" to remove that data section and you have a full page with no ads on the right side.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities